A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects
Clinical trial NCT07400744 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07400744
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-01
- Primary completion
- 2026-09-01
- Enrollment
- 102
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.